4-nitro-2-benzimidazolone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 4-nitro-2-benzimidazolone
• 英文别名: 4-Nitrobenzimidazol-2-one
• 化学式: C₇H₃N₃O₃
• 分子量: 177.119
• InChiKey: KMIFZILWRRENBO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  87.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  磷酸三丁酯 、 4-硝基邻苯二胺 在 尿素 作用下， 以 2-氯甲苯 、 水 为溶剂， 以95%的产率得到4-nitro-2-benzimidazolone
  参考文献：
  名称：

  Method for working up benzimidazolone-containing reaction mixtures

  摘要：

  本发明涉及一种处理反应混合物的工艺，所述混合物含有公式（I）的苯并咪唑酮 ##STR1## 通过在水不溶溶剂中反应邻苯二胺和尿素制备而成，其中在公式（I）中，R.sup.1、R.sup.2和R.sup.3是相同或不同的，且彼此独立地是氢原子、具有每种情况下1至6个碳原子的烷基、烷氧基或烷基磺酰基、氯、溴、取代或未取代的苯基、羧酸、甲基羰基、苯基羰基、甲氧羰基、氨基、甲氨基或苯氨基基团、羟基、氰基或硝基，通过向反应混合物中添加润湿剂和消泡剂，与搅拌并过滤掉从产生的水悬浮液中的苯并咪唑酮，采用加水和加热的方式，将溶剂与水共沸蒸馏。

  公开号：

  US06124470A1

文献信息

• [EN] TRICYCLIC COMPOUNDS AS TEC KINASE INHIBITORS<br/>[FR] COMPOSÉS TRICYCLIQUES À TITRE D'INHIBITEURS DE KINASES TEC
  申请人：GLENMARK PHARMACEUTICALS SA

  公开号：WO2013153539A1

  公开（公告）日：2013-10-17

  The present invention is directed to tricyclic compounds of formula (I) as Tec kinase inhibitors, in particular ITK (interleukin-2 inducible tyrosine kinase) inhibitors. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders mediated by ITK.

  本发明涉及公式（I）的三环化合物，作为 Tec 激酶抑制剂，特别是 ITK（白细胞介素-2诱导酪氨酸激酶）抑制剂。本文还提供了制备所述化合物的方法，用于合成它们的中间体，它们的药物组合物，以及治疗或预防由 ITK 介导的疾病、症状和/或紊乱的方法。
• IMMUNOGENIC COMPOSITIONS FOR GRAM POSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE
  申请人：Bell Ian M.

  公开号：US20090221535A1

  公开（公告）日：2009-09-03

  The present invention is directed to compounds of Formula I: I (where A 1 , A 2 , B 1 , B 2 , B 3 , B 4 , D 1 , D 2 , T, U, V, W, X, Y, Z. R 4 , R 5a ?, R 5b , R 5c , R 6 , m and n are defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及式I的化合物：I（其中A1、A2、B1、B2、B3、B4、D1、D2、T、U、V、W、X、Y、Z、R4、R5a？、R5b、R5c、R6、m和n在此定义），用作CGRP受体的拮抗剂，用于治疗或预防CGRP参与的疾病，如头痛、偏头痛和群头痛。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在预防或治疗CGRP参与的这些疾病中的使用。
• Tricyclic Anilide Spirolactam Cgrp Receptor Antagonists
  申请人：Bell Ian M.

  公开号：US20080214511A1

  公开（公告）日：2008-09-04

  The present invention is directed to compounds of Formula I: I (where A 1 , A 2 , B 1 , B 2 , B 3 , B 4 , D 1 , D 2 , J, K, T, U, V, W, X, Y, Z, R 4 , R 5a , R 5b , R 5c , m and n are defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及式I的化合物：I（其中A1，A2，B1，B2，B3，B4，D1，D2，J，K，T，U，V，W，X，Y，Z，R4，R5a，R5b，R5c，m和n在此定义），用作CGRP受体的拮抗剂，并用于治疗或预防CGRP参与的疾病，例如头痛、偏头痛和群集性头痛。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗CGRP参与的这些疾病中使用这些化合物和组合物的用途。
• Spirolactam Tricyclic CGRP Receptor Antagonists
  申请人：Bell Ian M.

  公开号：US20090105219A1

  公开（公告）日：2009-04-23

  Compounds of formula I: (wherein variables A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , B 1 , B 2 , B 3 , B 4 , D 1 , D 2 , E 1 , E 2 , E 3 , E 4 , E 5 , G 1 , G 2 , J, K, T, U, V, W, X, Y and Z are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  化合物I的公式为：（其中变量A1，A2，A3，A4，A5，A6，A7，B1，B2，B3，B4，D1，D2，E1，E2，E3，E4，E5，G1，G2，J，K，T，U，V，W，X，Y和Z如本文所述），这些化合物是CGRP受体拮抗剂，可用于治疗或预防CGRP参与的疾病，如偏头痛。本发明还涉及含有这些化合物的药物组合物以及这些化合物和组合物在预防或治疗CGRP参与的疾病方面的使用。
• Spirohydantoin Tricyclic CGRP Receptor Antagonists
  申请人：Bell Ian M.

  公开号：US20090281080A1

  公开（公告）日：2009-11-12

  Compounds of formula I: (wherein variables A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , B 1 , B 2 , B 3 , B 4 , D 1 , D 2 , E 1 , E 2 , E 3 , E 4 , E 5 , G 1 , G 2 , R 6 , T, U, V, W, X, Y and Z are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  公式I的化合物：（其中变量A1，A2，A3，A4，A5，A6，A7，B1，B2，B3，B4，D1，D2，E1，E2，E3，E4，E5，G1，G2，R6，T，U，V，W，X，Y和Z如本文所述），这些化合物是CGRP受体的拮抗剂，对于治疗或预防CGRP参与的疾病，如偏头痛，具有用途。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗CGRP参与的这些疾病中使用这些化合物和组合物的用途。